Back to Search
Start Over
O1-1 Second-line tislelizumab vs chemotherapy in advanced or metastatic ESCC: RATIONALE 302 Japanese subgroup.
- Source :
-
Annals of Oncology . 2022 Supplement 6, Vol. 33, pS468-S468. 1p. - Publication Year :
- 2022
- Subjects :
- *CANCER chemotherapy
*METASTASIS
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 158119959
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.05.018